Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.570
-0.040 (-2.48%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Allogene Therapeutics Stock Forecast
ALLO's stock price has decreased by -53.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Allogene Therapeutics stock have an average target of 9.66, with a low estimate of 4.60 and a high estimate of 14. The average target predicts an increase of 515.29% from the current stock price of 1.57.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2025.
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +409.55% | Mar 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +791.72% | Mar 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +536.94% | Mar 14, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +218.47% | Mar 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +473.25% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
15.30K
from 22.00K
Decreased by -30.45%
Revenue Next Year
16.69K
from 15.30K
Increased by 9.07%
EPS This Year
-1.24
from -1.32
EPS Next Year
-1.28
from -1.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 105,000 | 147.2M | ||
| Avg | 15,300 | 16,687 | 48.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 377.3% | 586.3% | 882,133.1% | ||
| Avg | -30.5% | 9.1% | 292,909.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.85 | -0.67 | -0.99 | ||
| Avg | -1.24 | -1.28 | -1.38 | ||
| Low | -1.53 | -1.81 | -2.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.